Clinical trial
Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To…
NCT00340080 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00340080 |
|---|---|
| Title | Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity |
| Official title | A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*5701) for Susceptibility to Abacavir Hypersensitivity |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Drug |
| Interventions | Abacavir |
| Enrollment | 1,806 |
| Start date | Apr 1, 2006 |
| First posted | Jun 21, 2006 |
| Last update posted | Jan 25, 2010 |
| Countries | Australia, Austria, Belgium, France, Germany, Ireland, Israel, Italy, Latvia, Netherlands, Norway, Poland and 7 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: